FDA 483 - MSN LIFE SCIENCES PRIVATE LIMITED - September 13, 2024

Between September 9 and September 13, 2024, the U.S. Food and Drug Administration (FDA) conducted an inspection of MSN Life Sciences Private Limited, Unit II, an active pharmaceutical ingredient (API) manufacturing facility located in Telangana, India. The inspection identified several significant deficiencies in the site’s quality management systems and physical infrastructure.

The primary violations involve the quality unit"s failure to thoroughly investigate testing failures and batch discrepancies. Specifically, the FDA noted that the firm did not provide adequate justification for invalidating "Out-of-Specification" test results. In several instances, human errors and equipment suitability failures were not documented or investigated as separate quality events, which prevents the company from accurately tracking and trending recurring manufacturing problems. Additionally, the quality unit failed to establish and monitor "Out-of-Trend" results for various products, neglecting a core responsibility to ensure consistent product performance. Regarding the physical plant, the inspection revealed that hand-washing stations used by personnel before entering cleanrooms lacked hot water.

These findings were issued as a Form 483, representing observations that require a formal response from the company. MSN Life Sciences is expected to submit a detailed plan of corrective actions to the FDA. While these observations do not constitute a final determination of compliance, the company must demonstrate how it will resolve these issues to align with regulatory expectations for pharmaceutical manufacturing.